Effect of Local Anesthesia Position of Lidocaine Injection on the Success Rate of Radial Artery Puncture Tube
Launched by TING XU · May 20, 2024
Trial Information
Current as of February 12, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Group A was randomly divided into two groups: 1% lidocaine 1 ml was injected above the artery during local anesthesia before arterial catheterization; Group B: 1ml of 1% lidocaine was injected into the right side of the artery. The proportion of subjects according to the number of PO was similar in all groups. After the screening, the scientific research personnel of each testing center will log in the random system, fill in the screening information, obtain the random number information, and distribute the corresponding scientific research drugs according to the random number. The total nu...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. ASA Class I-III, patients aged 18-80 years
- • 2. Planned surgery with radial artery catheterization
- • 3. Allen test negative
- • 4. Sign the informed consent form and voluntarily participate in this trial
- Exclusion Criteria:
- • 1. Inflamed skin at puncture site
- • 2. Extremely nervous and unable to cooperate
- • 3. Ultrasonographic assessment of aberrant radial artery
- • 4. Significant abnormalities in coagulation function (PT prolongation exceeding the upper limit of normal for 3 s or APTT prolongation exceeding the upper limit of normal for 10 s)
- • 5. The patient had undergone radial artery catheterization in the same arm in the past week
- • 6. History of hypersensitivity to local anesthetics
About Ting Xu
Ting Xu is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous scientific methodology and ethical standards, Ting Xu oversees the design, implementation, and management of clinical trials across various therapeutic areas. The organization collaborates with leading healthcare professionals and institutions to ensure the highest quality of data collection and analysis. By prioritizing patient safety and compliance with regulatory requirements, Ting Xu aims to contribute significantly to the development of effective treatments and enhance the understanding of complex medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chengdu, Sichuan, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0